Micropep Advances Global Commercialization of Peptide Biofungicide with U.S. and EU Regulatory Filings

Expanding Promisin™ Global Commercialization Pathway Across Key Agricultural Markets

Research Triangle Park, N.C. & Toulouse, France — July 28, 2026

Micropep Technologies announced on July 28, 2026, the submission of regulatory dossiers for Promisin™ in the United States and the European Union. This major milestone expands the company’s regulatory footprint across North America, Europe, and Latin America following earlier filings in Brazil and Paraguay.

Innovative Peptide-Based Biofungicide

Developed using Micropep’s proprietary Krisalix™ platform, Promisin™ is a lead peptide-based biofungicide targeting fungal diseases in grapevine and potato (for US/EU markets) alongside soy diseases in Latin America. Backed by more than three years of development and 200 field trials across diverse geographies, Promisin combines a novel mode of action with row-crop economics.

“The completion of our U.S. and EU regulatory submissions represents a defining milestone for Micropep and validates years of scientific innovation and field development for Promisin.”

— Dr. Kevin Leiner, Chief Regulatory Officer at Micropep

Key Attributes for Commercial Agriculture

Promisin was designed to help growers combat disease resistance and meet tightening environmental requirements while maintaining high performance:

Broad-spectrum activity against major fungal diseases
Novel peptide-based mode of action supporting resistance management
Fully compatible with existing crop protection programs for rotation or tank-mixing
Favorable safety and environmental profile with no residue concerns

“Opening the door to a new generation of products for growers worldwide.”